Mediscience Tecnology Corp.
Home   About   Investor Relations   News   Intellectual Property   Products   Alliances
  CD Ratiometer (CD-R) Cervix
 

Overview

 
 

Our Facility

 
 

Compact Photonic Explorer (CPE)Diagnostic Pill

 
 

CD Ratiometer

 
 

CD Scan

 
 

CD Map

 
 

Photo Gallery

 
 

FDA Clinical Trials

 
 

Research & Development

 

Overview

Designed as a fundamental, compact instrument with user friendly features and characteristics, the CD Ratiometer optically assesses the scanned tissue only at pre-established optical wavelengths. Moreover, it instantaneously reports out a "yes", "no", or "maybe" result viewed on a CRT screen.

Assuredly, the CD Ratiometer, with its assortment of disposable probe designs, will be the preferred product for medical practitioners to use in the office or clinical setting.

Clinical Validation-Pilot Study

  • IDE submission December 2005
  • Goals of Pilot Study
    – Optical spectroscopy to define specific state of tissues
    – Emission from tissues provide information for cancer and pre cancer
  • Clinical documentation to support safety and efficacy
  • To confirm sensitivity and specificity; significantly improved outcomes versus the standard (i.e., Pap smear)

Diagnostic Device

Current Prototype Future Packaged Device
  • Dual channel detector
  • Algorithms based on intensity ratios
  • Multiple wavelength pairs
  • Fast data acquisition (< 2 sec/ ratio)
  • Probes - Free standing, adapts to endoscopes, colposcopes, fiber needles

Market Size

  • 190,000 deaths annually worldwide
  • 371,000 new cases each year
  • 3,410 deaths annually in U.S.
  • 10,370 new cases annually in U.S.
  • 27% of all cancer in African women
  • 18% of all cancer in South American and Indian women
  • 55 million Pap smears annually in the U.S. and Europe
  • Two million Colposcope exams annually in the U.S. and Europe

The Worldwide market for Cervical Cancer diagnostics in constant dollars is in excess of $1.5 Billion.

Features and Benefits

  • 25 Patents covering cancer detection and tissue spectroscopy
  • Real-time results – CD-R provides a non-invasive, real-time, point-of-care diagnosis during an annual routine gynecological exam
  • Reduced sampling errors
  • No pain or bleeding
  • Reimbursement anticipated
  • Proprietary algorithms collect the maximum range of diagnostic information available
  • System is module and will contain a disposable sheath
  • Increased accuracy – CD-R has displayed sensitivity and specificity equal or greater than 95% in laboratory tests
 
     Copyright © 2004 Mediscience Technology Corp. Contact Us